The funding is provided as part of the ATLAS V2 project, which is part of the France 2030 program. France 2030 offers ...
Eli Lilly's research and development head said on Monday the company will have plenty of supply to launch its ...
Ribupatide (KAI-9531) aims to address critical need for greater weight loss, especially for people living with a BMI of 35 kg ...
Comprehensive comparison of daily oral vs weekly injectable Wegovy following Novo Nordisk's January 2026 FDA approval of the ...
Morning Overview on MSNOpinion
Inside the multimillion-dollar race to dim the sun and halt climate chaos
Vast sums of private and public money are now chasing a once-fringe idea: deliberately reflecting a slice of sunlight back ...
A new Top 10 Cybersecurity Innovators profile by AppGuard has been released, spotlighting growing concerns over AI-enhanced ...
Novartis has significantly strengthened its neuroscience pipeline over recent years, topped by the $12bn acquisition of ...
Many jails and prisons around the country don't provide medication treatment for opioid use disorder. Studies show that ...
Zacks Investment Research on MSN
Novo Nordisk soars 19% in a month: How should you play the stock?
Novo Nordisk NVO shares have surged 18.8% in the past month. The stock price gain was primarily induced by the ...
Christa Gail Pike argued in her filing that the new protocol, which relies on one drug instead of three, violates the U.S.
An economist identified factors that will increase pressure on consumer purchasing power this year in Indonesia ...
US FDA accepts Camurus’ resubmission of NDA for Oclaiz for treatment of acromegaly: Lund, Sweden Monday, January 12, 2026, 15:00 Hrs [IST] Camurus, an international, science-led ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback